Authors
Latest:
Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.
Latest:
Achieving Health Equity in Lung Cancer SurgeryRian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.
Latest:
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETsRead about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Latest:
Telemedicine Use in Oncology PracticesABSTRACT Telemedicine (TM) will play an increasingly significant role in practices that diagnose cancers and treat patients. Although only a small percentage of oncologists currently use TM, many more will embrace this technology in the near future. Although TM has been available for several decades, it was the coronavirus disease 2019 pandemic that highlighted how useful the concept was for connecting and communicating not only with patients who live a significant distance away from their oncologist’s brick-and-mortar office, but with those who are homebound, for whatever reason. For instance, patients who have tested positive for coronavirus but who are not significantly symptomatic can be safely treated while they remain at home. One barrier to the widespread implementation of TM was lack of compensation for the time spent communicating with patients using audio-visual technology. As of March 2020, however, CMS has mandated that TM virtual visits and face-to-face visits have financial parity. This article will explore the process of implementing TM into an oncology practice with minimal time, energy, effort, and expense, as well as the concepts and the trends behind using TM to provide care for patients with cancer.
Latest:
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural EffusionThis case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
Latest:
Disease Progression Links to QOL With Cemiplimab/Chemo in Penile CarcinomaThere were no new safety signals with cemiplimab plus chemotherapy in the phase 2 EPIC-A trial, Challapalli stated.
Latest:
Looking Ahead in the Multiple Myeloma Treatment LandscapeExperts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.
Latest:
Use of Immunotherapy in Patients With Cancer During the COVID-19 PandemicThis article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Latest:
Exploring Novel Treatment Options in Patients With RRMMThe panel closes by sharing final thoughts in the management of relapsed/refractory multiple myeloma, with a shared sense of optimism for advancements in treatment.
Latest:
Patient Case Presentation: Patient on ESA for First-Line Therapy and Not Receiving a Marked Response—What Do You Do Next, and Why?Panelists discuss management strategies for a patient with low-risk myelodysplastic syndrome with erythropoiesis-stimulating agent (ESA) failure, weighing options between initiating luspatercept or escalating ESA dosage while emphasizing the need for thorough evaluation of reversible causes before advancing therapy.
Latest:
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid LeukemiaInvestigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Latest:
Uterine Transposition May Maintain Fertility Following Pelvic RadiotherapyUterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.
Latest:
Best Treatment Selection in Clear-Cell RCCMedical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Latest:
Future Directions in Advanced Endometrial CarcinomaClosing the discussion on advanced endometrial carcinoma, Dr David O’Malley shares his perspective on the future treatment landscape.
Latest:
Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal DiseaseThis retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.
Latest:
Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AMLSingle-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.
Latest:
Patient Case Presentation: A 69-Year-Old With Newly Diagnosed EGFR-Mutant mNSCLC and Symptomatic Brain MetastasesPanelists discuss how a 69-year-old woman with newly diagnosed EGFR-mutant mNSCLC and symptomatic brain metastases requires immediate multidisciplinary care including steroids, radiation oncology consultation, and potential hospitalization, with treatment approach favoring stereotactic radiosurgery for dominant lesions followed by combination therapy like FLAURA2, while emphasizing that asymptomatic patients might allow for initial tyrosine kinase inhibitor treatment with close monitoring before considering radiation to potentially reduce treatment field and minimize long-term neurotoxicity.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Real-World Data Support Dostarlimab Combo Benefit in RUBY TrialSelect comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Latest:
Best Practices for the Medical Oncology BoardsA group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
Latest:
Declan Murphy, MB, BCh, on Rate of Equivocal Findings on PSMA PET/CT in Patients With Prostate CancerMurphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.
